Strategies for Global Clinical Trials: Clinical Research Without Borders

Navigating the global clinical trial landscape is an essential part of an interconnected world. Clinical trials are instrumental in advancing medical progress and improving health on a global scale. However, translating clinical trial operations to an international context involves a deep understanding of regulatory environments across countries and the agility to adapt swiftly to their changes.

Join this webinar to hear experts address these critical dimensions of global clinical trials and dissect the disparity between what many organizations claim about their global capabilities and the operational experience they can genuinely deliver. This gap can significantly influence the quality, speed and success of a clinical trial.

This webinar will help demystify the complexities of global clinical trials, striving towards a more efficient and inclusive research environment. The speakers will also explore how clinical trials are contributing to advancements in healthcare globally.

Register for this webinar today to broaden the knowledge required for achieving success in the rapidly evolving landscape of global clinical trials.

Speakers

Afshawn Chakamian, Director, Program Management, Avidity Biosciences

Afshawn Chakamian is a Director of Program Management at Avidity Biosciences, a biotech company focused on addressing unmet patient needs across rare diseases. Prior to joining Avidity, she spent 13 years in the CRO space at PRA and ICON where she learned the ins and outs of running clinical trials. Afshawn spent 7 years specifically focused on managing global rare disease clinical trials and has experience managing trials in all regions of the world, including Latin America and the Middle East.

Message Presenter

KimberLee Heidmann, EVP, Patient Experience and Customer Success, Scout

KimberLee Heidmann’s career in life sciences began in 1998 with her work at a subsidiary of the World Health Organization. She joined Scout (at that time, Meeting Protocol Worldwide) in 2001 and has served in multiple capacities over her 23-year tenure. KimberLee was part of the core team of innovators responsible for the realization and successful implementation of Scout Clinical and Scout Academy services. She also played a pivotal role in the organization’s 2024 rebrand as Scout. Her passion lies in driving transformative change in the clinical research field, creating inclusive pathways to research care for patients regardless of factors such as location, economic status, age, gender, disability or race.

Message Presenter

Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Cellular and Genetic Medicines, Worldwide Clinical Trials

Dr. Amy Raymond has been a drug discovery and development professional for over 20 years, including progressive roles in rare disease clinical operations and rare disease clinical strategy. Her clinical development experience spans all therapeutic areas and all stages of the clinical development lifecycle, from natural history studies through in-patient Phase I trials, and long-term follow up and post marketing surveillances.

Message Presenter

Scott Schliebner, Vice President and Global Head, Drug Development Consulting, Novotech

Scott Schliebner is a commercially-oriented clinical drug development executive with 30 years of experience across the biopharma, CRO and non-profit sectors. Through his leadership, vision and strategic approach, Scott takes people, teams and organizations further than they would otherwise go. Active as a Clinical Executive, Strategic Advisor, Board Member, patient advocate and mentor, Scott is regularly invited to speak on topics such as patient-focused research, clinical research outsourcing dynamics, rare disease drug development and building innovative research paradigms to engage with challenging patient populations. He received a Master’s Degree in Public Health in Biostatistics from the University of Utah School of Medicine and completed a Graduate Research Fellowship at The National Institutes of Health/NINDS. Scott currently serves as Vice President and Global Head of Drug Development Consulting at Novotech, a leading biotechnology CRO.

Message Presenter